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Current trends in the epidemiology, outcome and vari-
ables influencing mortality in bacteremic lung trans-
plant recipients have not been fully described. We
prospectively studied bacteremias in lung transplant
recipients in a multicenter study between 2000–2004.
Bacteremia was documented in 56 lung transplant
recipients, an average of 172 days after transplanta-
tion. Multiple antibiotic resistance was documented in
48% of the isolates; these included 57% of the Gram-
negative and 38% of the Gram-positive bacteria. Pul-
monary infection was the most common source of re-
sistant gram-negative bacteremias. Mortality rate at
28 days after the onset of bacteremia was 25% (14/56).
Mechanical ventilation and abnormal mental status
correlated independently with higher mortality (p <
0.05 for both variables). Bacteremia remains a signif-
icant complication in lung transplant recipients and
is associated with considerable mortality. Recognition
of variables portending a high risk for antibiotic resis-
tance and for poor outcome has implications relevant
for optimizing antibiotic prescription and for improv-
ing outcomes in lung transplant recipients.
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Introduction
The unique susceptibility of lung transplant recipients to
infectious complications is well recognized. Infections are
also a significant contributor to poor outcome, account-
ing for 25–37% of the post-transplant deaths in these
patients (1–3). Bacteremias are an important infection in
organ transplant recipients (4,5). In comparison to other
major infections however, e.g. fungal and viral infections,
there is striking paucity of systematically conducted stud-
ies on bacteremias in lung transplant recipients (1,6). In
a study in adult lung transplant recipients conducted be-
tween 1992–98, the overall incidence of bacteremia was
25% and staphylococci were the most common etiologic
agents (1).
Immunosuppressive regimens, patient characteristics and
antimicrobial prescription practices have continued to
evolve and are likely to have an impact on infectious com-
plications after lung transplantation (7,8). The goals of this
study were to determine the spectrum of bacteremias, as-
sess risk factors for bacteremia due to antibiotic-resistant
bacteria and determine the outcome in bacteremic lung
transplant recipients.
Methods
The study population comprised prospectively identified lung transplant re-
cipients with bacteremia at our institutions between July 2000 and Febru-
ary 2004. Institutional review board approval was obtained as per local re-
quirements. Immunosuppression and antimicrobial prophylaxis was admin-
istered according to the standard practice at each institution. Immunosup-
pressive regimen was tacrolimus based at one and cyclosporine based at
the other sites. Two of the study sites utilized T-cell induction with IL-2 re-
ceptor antibodies or rabbit antithymocyte globulin. Antimicrobial prophylaxis
employed at the participating sites is outlined in Table 1.
Definitions
Definition of bacteremia and determination of its source was based
on the criteria proposed by the Centers for Disease Control and Pre-
vention and as previously reported in transplant recipients (9,10). Iso-
lation of bacteria from a single blood culture in the presence of clini-
cal symptoms or signs of infection was considered true bacteremia (9).
Bacteremia caused by common skin contaminants was considered signifi-
cant only if the organism was isolated from ≥ 2 blood cultures and clinical
manifestations of infection were present (9). Bacteremia was considered
primary if the offending pathogen was not related to infection at another
site or if it was vascular-catheter related (9). The source was considered
pulmonary if the same bacteria was also isolated from the pleural fluid or
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Table 1: Antimicrobial prophylaxis employed at the participating
sites
Institution Antimicrobial prophylaxis
Toronto General Hospital Cefuroxime for 48 h unless cystic
fibrosis was present, in which case
the perioperative antibiotics were
based on the colonizing organisms
and continued for 2 weeks.
Patients with cystic fibrosis also
received inhaled tobramycin.
Henry Ford Hospital Vancomycin plus ceftazidime or
cipro-floxacin for 7 days. In
patients with cystic fibrosis,
antibiotics were adjusted based on
perioperative cultures.
Duke University Vancomycin plus ceftazidime for
7–10 days. Antibiotics were
modified based on donor bronchial
washing isolates and perioperative
cultures in cystic fibrosis patients.
Inhaled colistin and tobramycin
were also employed for 3 months
in patients with cystic fibrosis.
University of Pittsburgh Ceftazolin plus aztreonam for 48 h.
Antibiotic selection was based on
perioperative cultures in patients
with cystic fibrosis.
respiratory tract cultures, including bronchoalveolar lavage in the presence
of clinical signs and symptoms of pneumonia (9).
Multiple-antibiotic resistance was defined as enterococci resistant to van-
comycin; S. aureus resistant to methicillin; enterobacteriaceae resistant to
at least two of the following: extended spectrum penicillins, quinolones,
third-generation cephalosporins, or aminoglycosides; and P. aeruginosa
or other nonfermenting Gram-negative bacteria resistant to at least two
of the following: extended spectrum penicillins, quinolones, generation
cephalosporins, aztreonam, carbapenems, or aminoglycosides (11,12). Prior
antibiotic use was defined as use of antibiotics for ≥ 1 day within 14 days
preceding the onset of bacteremia. Discordant antibiotic therapy was de-
fined as receipt for the first 2 days (after the blood culture was obtained)
of an antibiotic agent or regimen that was inactive in vitro against the bac-
teria subsequently isolated in the blood culture (13). T-cell antibodies were
classified as nondepleting (IL-2 receptor antibodies such as basiliximab or
dacluzimab) or depleting (antithymocyte globulin) depending upon whether
they reduce responsiveness of T-cells with or without depleting them (14).
Statistical analysis
Statistical analysis was conducted using STATA (Intercooled Stata 7.0, Col-
lege Station, TX). Categorical data were compared using the Fisher exact
test. The Mann-Whitney test was used to compare continuous data and
was constructed to examine the effects of multiple risk factors on outcome.
Factors significant at the level of 0.05 or lower by univariate analysis were
analyzed in a logistic regression model and considered to be significant if
p-value was ≤ 0.05.
Results
Bacteremia was documented in 56 lung transplant recip-
ients. These included 35 of 305 patients who underwent
Table 2: Demographic and clinical characteristics of the study
patients
Number of patients 56














Chronic obstructive pulmonary disease 42.9% (24/56)
Cystic fibrosis 19.6% (11/56)
Sarcoidosis 12.5% (7/56)
Pulmonary fibrosis 8.9% (5/56)
Alpha-1 antitrypsin deficiency 5.3% (3/56)




Cyclosporine A 19.6% (11/56)
Azathioprine 44.6% (25/56)
Mycophenolate mofetil 33.9% (19/56)
Sirolimus 5.3% (3/56)
Prednisone 21.4% (12/56)
T-cell antibody induction 37.5% (21/56)
Diabetes mellitus 35.7% (20/56)
Renal failure∗ 23.2% (13/56)
Dialysis 19.6% (11/56)
∗Defined as creatinine > 2.0 mg/dL.
Other includes silicosis 1, rheumatoid lung 1, eosinophilic lung
disease 1 and bronchiolitis obliterans 1.
lung transplantation during the study period, yielding an
incidence rate of 11.5%. The clinical and demographic char-
acteristics of the patients are outlined in Table 2. Pulmonary
(46%, 26/56) and vascular catheter infections (41%, 23/56)
accounted for a majority of the episodes of bacteremia; the
latter included 14 long-term access (dialysis or implantable
catheters) and 9 short-term (or central venous catheters).
In all, 52% (29/56) of the bacteremias were due to Gram-
negative and 46% (26/56) due to Gram-positive bacteria;
one patient had bacteremia due to both P. aeruginosa and
MRSA (Table 3). Pseudomonas aeruginosa (23%, 13/56),
Burkholderia cepacia (9%, 5/56) and Klebsiella pneumo-
niae (7%, 4/56) were the most commonly documented
Gram-negative bacteria. These bacteria accounted for 67%
of all episodes of bacteremia resulting from a pulmonary
source. S. aureus was the predominant Gram-positive
pathogen associated with bacteremias. Vascular catheters
followed by pulmonary infection were the most frequently
documented sources of S. aureus bacteremia (Table 3).
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Table 3: Pathogens associated with bacteremia stratified by the source
Source of the bacteremia
Bacteria Pulmonary Vascular catheter Surgical site Urinary tract Abdominal Total
Gram-negative
Glucose nonfermenters
Pseudomonas aeruginosa 8 4 - - - 12
Burkholderia cepacia 4 - 1 - - 5
Acinetobacter baumanii 1 - - - - 1
Stenotrophomonas maltophilia - 1 - - - 1
Pandoraea pnomenosa 1 - - - - 1
Glucose fermenters
Klebsiella pneumoniae 3 - - - 1 4
Serratia marcesens - 2 - - - 2
Proteus mirabilis - 1 - - - 1
Pantoea agglomerans 1 - - - - 1
Gram-positive
MRSA∗ 2 3 1 - - 6
MSSA∗∗ 1 1 - - - 2
VRE† 1 1 - - 1 3
Enterococcus fecalis - 4 - - 1 5
Staphylococcus epidermidis 1 3 - - - 4
Staphylococcus hominis - 1 - - - 1
Viridans streptococci 1 - - - - 1
Streptococcus pneumoniae 1 - - - - 1
Clostridium spp. - - - - 1 1
Corynebacterium spp. - 1 - - - 1
Polymicrobial
P. aeruginsosa + P mirabilis - - - 1 - 1
P. aeruginosa + MRSA 1 - - - - 1
E. fecalis + S. epidermidis - 1 - - - 1
Total 26 23 2 1 4 56
∗MRSA = methicillin-resistant S. aureus.
∗∗ MSSA = methicillin-sensitive S. aureus.
†VRE = vancomycin-resistant Enterococcus faecium.
Enterococci were the second most commonly occurring
Gram-positive etiologic agents for bacteremia (Table 3).
Time to onset
The median time to onset of bacteremia after transplan-
tation was 172 days (interquartile range 45–423 days).
In all, 20% of the bacteremias occurred within 30 days,
18.2% between 30–90 days, 34.5% between 91 days–1
year and 27.3% >1 year posttransplantation. Pulmonary
infection was the most frequently documented source of
bacteremia up to one year after transplantation; 54.5% of
the bacteremias within 30 days, 40% between 31-90 days
and 52.6% between 91 days-–1 year posttransplant were
of pulmonary origin. After 1 year, the leading portal of entry
was vascular catheters (53.3%) whereas pulmonary infec-
tions accounted for 26.7% of the bacteremias during this
period. Only 7% (1/14) of the catheter-related infections
within 1 year compared to 50% (4/8) after 1 year post-
transplant were due to dialysis catheters.
Since bacteremias occurring within 30 days of transplanta-
tion may be amenable to antimicrobial prophylaxis, we ana-
lyzed variables associated with early (within 30 days post-
transplant) versus late-onset bacteremia (after 30 days).
Patients with early onset bacteremias were significantly
more likely to still be intubated at 30 days and to have re-
ceived T-cell depleting antibody induction (Table 4). Other
clinically relevant variables did not differ for the two groups
(Table 4).
Bacteremia due to multiple antibiotic-resistant
bacteria
Multiple antibiotic resistance was documented in 48%
(27/56) of the isolates. A total of 57% (17/30) of the Gram-
negative bacteremias were due to multiply-antibiotic re-
sistant bacteria; these included 50% of the Pseudomonas
aeruginosa, 100% of the Burkholderia cepacia and 50%
of the Klebsiella pneumoniae isolates. Pulmonary infection
was the most common source of resistant Gram-negative
bacteremias (71%, 12/17). In all, 35% (6/17) of the patients
with cystic fibrosis compared to 8% (1/13) with other un-
derlying lung diseases had resistant Gram-negative bac-
teremia (p = 0.10) (Table 5). When patients with B. cepacia
were excluded, the proportion of patients with cystic fibro-
sis who had bacteremia due to multiple antibiotic-resistant
Gram-negative bacteria was similar to noncystic fibrosis
patients (50%, 1/2 vs. 48%, 11/23, p = 0.99).
3002 American Journal of Transplantation 2006; 6: 3000–3007
Bacteremia and Lung Transplantation
Table 4: Variables associated with bacteremia occurring within 30 days (early-onset) versus after 30 days posttransplant (late onset)
Bacteremias within Bacteremia after
30 days 30 days
posttransplant posttransplant
Variable (n = 11) (n = 45) p Value
Univariate analysis
Age, median 52 54 0.27
Type of transplant
Bilateral 63% (7/11) 51% (23/45) 0.51
Underlying lung disease
Cystic fibrosis 27% (3/11) 18% (8/45) 0.67
Chronic obstructive pulmonary disease 36% (4/11) 42% (19/45) 0.99
Mechanical ventilation 82% (9/11) 27% (13/45) 0.002
Source of bacteremia
Pulmonary 54% (6/11) 42% (19/45) 0.51
Vascular-catheter 36% (4/11) 44% (20/45) 0.74
Antibiotic-resistant bacteria 45% (5/11) 49% (22/45) 0.99
Nonfermenter gram-negative bacteria 36% (4/11) 31% (14/45) 0.73
T-cell antibody use 67% (7/11) 31% (14/45) 0.051
Depleting T-cell antibody use 36% (4/11) 7% (3/45) 0.022
Multivariate analysis Odds ratio 95% CI
Mechanical ventilation 11.59 1.94 – 69.28 0.007
T-cell depleting antibody 8.66 1.13 – 66.10 0.03
Table 5: Factors associated with bacteremia due to multiple antibiotic-resistant versus sensitive Gram-negative bacteria
Factor Resistant (n = 17) Sensitive (n = 13) Significance level
Age, median (years) 52.5 55 0.15
Type of transplant
Bilateral 71% (12/17) 46% (6/12) 0.18
Single 29% (5/17) 46% (6/12)
Heart-lung 0 8%(1/13)
Underlying lung disease
Cystic fibrosis 35% (6/17) 8% (1/13) 0.10
COPD∗ 35% (6/17) 54% (7/13) 0.46
Alpha-1 antitrypsin deficiency 12% (2/17) 0/13 0.49
Sarcoidosis 12% (2/17) 8% (1/13) 0.99
Pulmonary fibrosis 6% (1/17) 15% (2/13) 0.56
Primary pulmonary hypertension 0/17 8% (1/13) 0.43
Other 0/17 8% (1/13) 0.43
Immunosuppression
Primary
Tacrolimus 82% (14/17) 69% (9/13) 0.66
Cyclosporine A 18% (3/17) 31% (4/13)
Mycophenolate mofetil 41% (7/17) 23% (3/13) 0.44
T-cell antibodies 29% (5/17) 31% (4/13) 0.99
Diabetes mellitus 47% (8/17) 31% (4/13) 0.46
Prior antibiotic use 65% (11/17) 23% (3/13) 0.03
Renal failure at baseline 18% (3/17) 15% (2/13) 0.99
Mechanical ventilation 53% (9/17) 15% (2/13) 0.06
Source
Pulmonary 71% (12/17) 46% (6/13) 0.26
Urinary tract 6% (1/17) 8% (1/13) 0.99
Vascular catheter 12% (2/17) 38% (5/13) 0.19
Intraabdominal 6% (1/17) 8% (1/13) 0.99
∗COPD = chronic obstructive pulmonary disease.
When variables associated with multiple antibiotic-
resistant versus sensitive Gram-negative bacteria were an-
alyzed, only prior antibiotic use correlated significantly with
antibiotic resistance (65%, 11/17 versus 23%, 3/13, p =
0.03) (Table 5). Of Gram-positive bacteria, 38% (10/26)
were multiple antibiotic-resistant; these included six
S. aureus and four enterococcal isolates. The only vari-
able significantly associated with resistant Gram-positive
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Table 6: Risk factors for bacteremia due to multiple antibiotic-resistant versus sensitive Gram-positive bacteria
Factor Resistant (n = 10) Sensitive (n = 16) Significance level
Age, median, years 49 53 0.48
Prior antibiotics 70% (7/10) 62.5% (10/16) 0.99
Type of transplant 0.42
Bilateral 60% (6/10) 37% (6/16)
Unilateral 30% (3/10) 56% (9/16)
Heart-lung 10% (1/10) 6% (1/16)
Underlying disease
Cystic fibrosis 20% (2/10) 12% (2/16) 0.63
COPD∗ 40% (4/10) 37% (6/16) 0.99
Alpha-1 antitrypsin deficiency 0/10 6% (1/16) 0.99
Sarcoidosis 20% (2/10) 12% (2/16) 0.63
Pulmonary fibrosis 10% (1/10) 6% (1/16) 0.99
Primary pulmonary hypertension 0/10 16%(1/16) 0.99
Other 10%(1/10) 19% (3/16) 0.99
Immunosuppression
Primary
Tacrolimus 70% (7/10) 81% (13/16) 0.64
Cyclosporine A 30% (3/10) 19% (3/16)
Mycophenolate mofetil 70% (7/10) 12% (2/16) 0.008
T-cell antibodies 60% (6/10) 37% (6/16) 0.42
Diabetes mellitus 30% (3/10) 31% (5/16) 0.99
Renal failure 20% (2/10) 25% (4/16) 0.99
Mechanical ventilation 60% (6/10) 44% (7/16) 0.69
Source
Pulmonary 20% (2/10) 25% (4/16) 0.99
Vascular catheter 60% (6/10) 62% (10/16) 0.99
Intraabdominal 0/10 12% (2/16) 0.51
Surgical site 20% (2/10) 0% (0/16) 0.14
∗COPD = chronic obstructive pulmonary disease.
bacteremias was the receipt of mycophenolate mofetil
(Table 6); resistant Gram-positive bacteremias in 5/7 my-
cophenolate mofetil recipients were due to MRSA.
Discordant initial antibiotic use
Twenty-one percent (12/56) of the bacteremic patients re-
ceived discordant antibiotics; these included 23.3% (7/30)
of those with Gram-negative and 19.2% (5/26) of those
with Gram-positive bacteremias. Receipt of discordant an-
tibiotics was documented in 28% (7/25) of the patients
with a pulmonary portal and in 9.1% (2/22) of those with
vascular catheters as the source of bacteremias. Patients
with cystic fibrosis received discordant antibiotics in 27.3%
(3/11) and those with COPD in 13% (3/23) of the cases.
The aforementioned differences, however, were not sta-
tistically significant.
Mortality
Overall mortality rate at 28 days in the patients with bac-
teremia was 25% (14/56). Mortality rate was 33% for pa-
tients with Pseudomonas aeruginosa, 20% for Burkholde-
ria cepacia, 17% for MRSA and 25% for those with en-
terococcal bacteremia. When stratified by time elapsed
since transplantation, mortality was 36.4% (4/11) for bac-
teremias occurring within 30 days, 30% (3/10) between
31–90 days, 26.3% (5/19) between 91 days–1 year and
20% (3/15) for bacteremias occurring >1 year post-
transplantation. In univariate analysis, abnormal mental sta-
tus, mechanical ventilation, Gram-negative bacteremia and
multiple antibiotic resistance were significantly associated
with mortality (Table 7). In a logistic regression model that
included the aforementioned variables, mechanical ventila-
tion and abnormal mental status independently correlated
with higher mortality (Table 7).
Discussion
Several observations based on our study are clinically rel-
evant with regards to bacteremia in lung transplant recipi-
ents. Thoracic organ transplant recipients are uniquely sus-
ceptible to pulmonary complications (15). Our data show
that 50% of the bacteremias in the first posttransplant year
were of pulmonary origin. After 1 year, the proportion of
bacteremias that were due to pulmonary infections de-
clined to 26.7% and vascular catheters emerged as the
leading source of bacteremia (53.3%). In lung transplant
recipients receiving calcineurin-inhibitor agents, renal fail-
ure is an increasingly recognized morbidity. Deterioration in
renal function typically ensues early (16,17), with 91% of
the patients experiencing renal dysfunction by 6 months
(16) and 5–8% ultimately requiring hemodialysis (17,18).
We note that one-half of the vascular catheter associated
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Table 7: Factors associated with mortality at 28 days in the study patients (univariate analysis)
Factor Died (n = 14) Lived (n = 42) Significance level
Univariate analysis
Age, median, years 50 49 0.58
Type of lung transplant
Bilateral 57.1% (8/14) 52.9% (22/42) 0.89
Unilateral 42.9% (6/14) 40.5% (17/42)
Heart-lung 0/16 7.1%(3/42)
Underlying disease
Cystic fibrosis 7.1% (1/14) 23.8%(10/42) 0.26
Chronic obstructive pulmonarydisease 57.1% (8/14) 35.7% (15/42) 0.21
Alpha-1 antitrypsin deficiency 14.3% (2/14) 2.4% (1/42) 0.15
Sarcoidosis 19% (2/14) 11.9% (5/42) 0.99
Pulmonary fibrosis 0/14 9.5% (4/42) 0.56
Primary pulmonary hypertension 0/14 11.9% (5/42) 0.32
Silicosis 6% (1/14) 0/42 0.25
Rheumatoid lung 0/14 2.4% (1/42) 0.99
Other 6%(1/14) 9.5% (4/42) 0.99
Immunosuprression
Primary
Tacrolimus 92.9% (13/14) 71.4% (30/42) 0.15
Cyclosporine A 7.1% (1/14) 28.6% (12/42)
Mycophenolate mofetil 50% (7/14) 28.6% (12/42) 0.19
T-cell antibodies 42.9% (6/14) 35.7% (15/42) 0.75
Diabetes mellitus 21.4% (3/14) 40.5% (17.42) 0.33
Renal failure 28.6% (4/14) 16.7% (7/42) 0.43
Signs & symptoms∗
Fever 64.3%(9/14) 76.2% (32/42) 0.48
Hypothermia 14.3% (2/14) 4.8% (2/42) 0.25
Abnormal mental status 78.6% (11/14) 4.8% (2/42) <.0001
Mechanical ventilation 100% (14/14) 35.7% (15/42) <.0001
Gram-negative bacteria 78.6% (11/14) 45.2% (19/21) 0.03
Multiple antibiotic-resistant bacteria 78.6% (11/14) 38.1% (16/42) 0.01
Discordant antibiotic use 42.8% (6/14) 14.2% (6/42) 0.05
Multivariate analysis Odds ratio 95% CI
Gram negative bacteremia 10.8 0.87 – 133.83 0.063
Mechanical ventilation∗∗ – – < 0.0001
Abnormal mental status 21.95 1.88 – 255.86 0.014
Multiple antibiotic resistance 5.17 0.51 – 51.95 0.162
∗Fever was defined as temperature of 100◦F or greater and hypothermia as temperature equal to or less than 95◦F (10).
∗∗The odds ratio and confidence intervals for mechanical ventilation could not be calculated as all patients with mechanical ventilation
died yielding an odds ratio that approached infinity because of zero value.
bacteremias after the first posttransplant year in our study
were dialysis catheter-related.
Assessment of trends in the epidemiology of bacterial in-
fections in immunosup-pressed hosts have often focused
on bloodstream infections as a benchmark (11,15,19). In
liver and heart transplant recipients, the proportion of
Gram-negative bacteremias have increased from 43.5%
and 57.9% in mid to late 1990s to 52% and 80% respec-
tively, in the current era. Gram-negative bacteria accounted
for 46% of the bacteremias in a previous study in lung
transplant recipients (1) and for 53% in ours. Notably, 57%
of the Gram-negative bacteremias in our report were due
to multiple antibiotic-resistant bacteria. While 35% of the
patients with antibiotic resistant bacteria had cystic fibrosis
compared to 8% of those with sensitive bacteria, cystic fi-
brosis per se was not significantly predictive of bacteremia
due to resistant bacteria. When B. cepacia was excluded,
the proportion of patients with cystic fibrosis and resistant
Gram-negative bacteremia (50%) was virtually identical to
that of patients without cystic fibrosis (48%). Overall, prior
antibiotic use was the only variable significantly associated
with resistant Gram-negative bacteremia.
Immunosuppression, particularly the use and type of in-
duction regimens for lung transplant recipients has evolved
considerably over the last decade (8). The use of induction
therapy has increased from 22% in 1997 to 50% in 2004.
Whereas antithymocyte globulin use decreased from 23%
in 1995 to 5% in 2004, the use of IL-2 receptor antibody
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increased from 0% in 1997 to 38% in 2004 (8). Receipt of
depleting T-cell antibody was a risk factor for bacteremia in
solid organ transplant recipients in one study (20), but not in
another (21). Patients who were still requiring mechanical
ventilation at 30 days and those receiving T-cell depleting
antibody were more likely to develop bacteremia within
30 days posttransplant. Whether modification of prophy-
laxis or selection of therapy that is based on prior cul-
ture data or other preventive strategies can curtail this
risk, remains to be determined. We caution, however,
that our data are based on a small sample size and
our findings therefore should be confirmed in future
studies.
The only variable that significantly correlated with the risk
of resistant (vs. sensitive) Gram-positive bacteremia was
mycophenolate mofetil use. Mycophenolate has potent in
vitro antifungal activity against P. jirovecii (22) and pos-
sesses antiviral activity against viruses such as flaviviruses
(23). However, it has no known antibacterial activity or di-
rect effects by which it may promote bacterial prolifera-
tion. The association between mycophenolate mofetil and
resistance (largely due to MRSA) could not be explained on
the basis of CMV infection, diabetes mellitus, neutropenia,
renal failure, or prior antibiotic use and may simply be an ar-
tifactual finding based on multifactorial analyses in a small
sample size.
Mortality rates in bacteremic transplant recipients have
ranged from 14% in kidney, 28–36% in liver and 59% in
heart transplant recipients (10,15,24). In lung transplant re-
cipients, mortality was 22% in patients with Gram-negative
and 33% in those with Gram-positive bacteremia (1). Over-
all mortality rate in bacteremic patients in our study was
25%. Mechanical ventilation at baseline and abnormal
mental status were associated with poor outcome. The
aforementioned variables while important with regards to
their prognostic implications are largely unamenable once
bacteremia has occurred. Discordant antibiotic use, on the
other hand, is a modifiable variable. Mortality rate was
43% in patients receiving discordant antibiotics and 14% in
those receiving concordant antibiotics (Table 7). Studies in
critically ill patients with sepsis and with ventilator associ-
ated pneumonia have shown similar results (25,26), In the
case of lung transplant recipients, the knowledge of sus-
ceptibility data of patients’ preoperative or post-transplant
isolates can be potentially valuable in guiding empiric an-
tibiotic selection, particularly in those with high rate of
colonization, for example, patients with cystic fibrosis or
bronchiectasis.
In summary, our data show that bacteremia remains a sig-
nificant complication in lung transplant recipients. Notably,
48% of the bacteremias were due to bacteria that demon-
strated multiple antibiotic resistance. These data suggest
that concerns regarding escalating trends in antibiotic re-
sistance in critically ill transplant recipients must be bal-
anced by the need for appropriate empiric antibiotic ther-
apy. In this context, periodic evaluation of evolving trends in
bacteremias has implications relevant for appropriate man-
agement and for optimal antibiotic prescription in these pa-
tients.
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